<DOC>
	<DOCNO>NCT00988624</DOCNO>
	<brief_summary>This study evaluate four different modify release formulation estimate amount dimebon available body relative current dimebon formulation give three time day . The result study help inform guide formulation development effort ultimate goal reduce dose frequency once-a-day twice-a-day .</brief_summary>
	<brief_title>A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon ( Latrepirdine )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subjects history previous seizure ( include childhood febrile seizure ) convulsion significant head trauma . Subjects hypersensitivity reaction dimebon antihistamine . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Smokers use great 5 cigarette per day . Use proton pump inhibitor , antacid , H2blockers prohibit duration study . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>bioavailability pharmacokinetics Alzheimer 's Disease Huntington Disease</keyword>
</DOC>